Merck Inc discontinues preladenant for Parkinsons disease
An initial review of data at Merck Inc.,from three separate Phase III trials for treatment of Parkinsons disease did not provide evidence of efficacy for preladenant compared with placebo.Based on these results, Merck is taking steps to discontinue the extension phases of these studies and no longer plans to pursue regulatory filings for preladenant. The decision to discontinue these studies is not based on any safety finding. The results of these studies will be presented at an upcoming scientific meeting and will be submitted for publication in a peer-reviewed journal.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins